- Home
- BGMS vs LYRA Comparison
BGMS vs LYRA Comparison
Compare BGMS & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGMS | LYRA |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BGMS | LYRA |
|---|---|---|
| Price | $0.91 | $1.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 17.3K | ★ 64.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,534,000.00 |
| Revenue This Year | $137.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $0.08 |
| 52 Week High | $6.70 | $37.50 |
Technical Indicators
Market Signals| Indicator | BGMS | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 40.29 |
| Support Level | $0.74 | $1.21 |
| Resistance Level | $1.12 | $1.52 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 54.96 | 72.12 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.